Related Experiment Videos
Evaluating the efficiency of targeted designs for randomized clinical trials
Richard Simon1, Aboubakar Maitournam
1Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892-7634, USA. rsimon@nih.gov
Summary
Targeted clinical trials can significantly reduce patient numbers by selecting individuals likely to respond to a drug. This approach enhances efficiency when the drug
Area of Science:
- Biomedical research
- Clinical trial design
- Genomic medicine
Background:
- Genomic technologies enable precise identification of patients likely to benefit from targeted therapies.
- This facilitates the development of targeted clinical trials with restricted eligibility criteria.
Purpose of the Study:
- To evaluate the efficiency of targeted clinical trial designs compared to traditional untargeted designs.
- To assess the impact of patient selection on trial resource requirements.
Main Methods:
- Comparative analysis of targeted versus untargeted randomized clinical trial designs.
- Evaluation of efficiency based on patient numbers for randomization and screening.
Main Results:
- The relative efficiency of targeted designs is influenced by the proportion of responsive patients, assay accuracy, and understanding of the drug's mechanism of action.
- Formulas were developed to quantify the efficiency gains of targeted over untargeted designs.
Conclusions:
- Targeted clinical trials offer substantial reductions in required patient numbers.
- This efficiency is maximized when the drug's mechanism of action is understood and a reliable responsiveness assay is available.